Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.30 |
| ▸ | PDE4A | P27815 | 2/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837900 | 0.78 | KMT2A (0.31) | LMNAMAPT | |
| SCHEMBL15988845 | 0.75 | KDM4E (0.66) | LMNAKDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL6837568 | 0.74 | FFAR4 (0.36) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL244899 | 0.71 | LMNA (0.37) | LMNAKDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL1256860 | 0.69 | CA1 (0.43) | ALDH1A1CYP3A4 | |
| SCHEMBL7071784 | 0.68 | KDM4E (0.40) | KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL17099983 | 0.67 | HTT (0.30) | — | |
| SCHEMBL6605094 | 0.67 | KDM4E (0.56) | LMNAKDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL27373488 | 0.66 | SMN1; SMN2 (0.50) | LMNAALDH1A1MAPT | |
| SCHEMBL15988872 | 0.65 | LMNA (0.59) | LMNAKDM4EALDH1A1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716987-B1 | PHOSPHODIESTERASE IV INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-6514996-B2 | Derivatives of benzofuran or benzodioxole | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-0943613-A1 | OXYGENIC HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1999-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | CBR1, CBR3, CYC1 | LMNA 1848/4885KDM4E 3975/4885ALDH1A1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.